CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
“Lilly is an industry leader
in Alzheimer’s research, with numerous ongoing scientific programs that target suspected causes of the disease, including
amyloid plaques and tau tangles,” said Mark Mintun, M.D., vice president of neurodegeneration and pain research at Lilly.
“This agreement with AC Immune represents another opportunity to hopefully make progress against this devastating disease,
and we look forward to together bringing tau aggregation inhibitors into clinical development.”
Prof. Andrea Pfeifer, CEO of
AC Immune, said: “This landmark partnership with Lilly is transformational for the future of AC Immune. Lilly’s substantial
experience in neurology, and particularly in Alzheimer’s disease, is a major validation of our small molecule platform for
CNS therapeutics. It also demonstrates the potential of our pre-clinical assets and adds substantial value to our pipeline. We
look forward to working closely with Lilly in this exciting field over the coming years.”
This transaction will be reflected
in Lilly's reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP). There will be
no change to Lilly's 2018 non-GAAP earnings per share guidance as a result of this transaction. This transaction is subject to
clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
About AC Immune’s Tau
Several chemical series of small
molecules (MorphomersTM) have been identified which selectively and potently reduce toxic intracellular misfolded and
aggregated tau. Targeting intracellular misfolded and aggregated tau is widely recognized as an important and attractive potential
approach for interfering with the spread of tau pathology throughout the brain. In some proof-of-concept tauopathy models, reduction
of tau pathology was also accompanied by a reduction of associated neuroinflammatory markers – another key pathologic feature
of Alzheimer’s disease (AD).
About AC Immune
AC Immune is a clinical-stage
Swiss-based biopharmaceutical company, listed on NASDAQ, which aims to become a global leader in precision medicine for neurodegenerative
diseases. The Company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify
diseases caused by misfolding proteins. AC Immune’s two proprietary technology platforms create antibodies, small molecules
and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer’s disease (AD). The
Company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates
currently in clinical trials.